For instance, Park et al. (2016) have elucidated the anti-cancer effects of the SIRT inhibitor MHY2256 on MCF-7 breast cancer cells through the modulation of the MDM2-p53 interaction, which is intimately connected to Sirt1 regulation [46]. This evidence concerns the gene TP53 and breast carcinoma.